Aravive — Investor Presentation (March 2021)
36 slides from Aravive's investor presentation, Mar 2, 2021
Slide 1: Corporate Presentation March 2021
Corporate Presentation March 2021 Halting Disease Progression in its Tracks ARAV (NASDAQ) Exhibit 99.1
Slide 2: Forward-Looking Statements
© 2021 Aravive, Inc. 2 Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking statements generally
Slide 3: Experienced Management and Board of Directors
3 Experienced Management and Board of Directors Board of Directors Senior Management CEO Gail McIntyre, Ph.D., DABT CMO Reshma Rangwala, M.D., Ph.D. Chairman of the Board Fred Eshelman, Pharm D. Director Amato Giaccia, Ph.D. Director Michael Rogers Director Eric Zhang CFO Vinay Shah SVP of Data Scie
Slide 4: Aravive Top Shareholders
4 Aravive Top Shareholders Insiders, Institutional Shareholders Make Up approx. 70% of Our Outstanding Shares * As per SEC filings – 13D, 13F, 13G, Forms 3 and Form 4, Proxy ** As of 12/31/2020, adjusted for Eshelman Ventures investment in Feb-21 © 2021 Aravive, Inc.
Slide 5: AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway
5 AVB-500: First- & Potential Best-In-Class in Targeting GAS6/AXL Pathway AVB-500 © 2021 Aravive, Inc.
Slide 6: GAS6/AXL Signaling Pathway
6 GAS6/AXL Signaling Pathway GAS6 and AXL are overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival GAS6 is growth factor that regulates several biologic processes in cells through interaction with its receptors, including AXL, Tyro3,
Slide 7: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers
GAS6 & AXL Expression Associated with Poor Survival in Many Cancers “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis” Wu G, et al. Molecular insights of Gas6/TAM in cancer development and therapy; Cell Death and Disease (2017) 8, e2700. 7 AXL expressed in >70% of
Slide 8: Unique and Potentially Superior Approach to Targeting GAS6/AXL Signaling
As an engineered decoy receptor with 200-fold higher affinity for GAS6 versus natural GAS6/AXL interaction, AVB-500 provides potent & selective inhibition of this signaling pathway. Other approaches targeting GAS6/AXL signaling have drawbacks: Tyrosine Kinase Inhibitors lack selectivity, leading to
Slide 9: Clinical Pipeline
OVARIAN CANCER Platinum Resistant (AVB-500 + AstraZeneca’s Durvalumab) 9 Forward-Looking Statements Clinical Pipeline Indication Preclinical Phase 1 Phase 3 Phase 2 Anti-CTGF AVB-500 IST at MDACC CANCER AND FIBROSIS OVARIAN CANCER Platinum Resistant (AVB-500 + Paclitaxel) CLEAR CELL RENAL CANCER 2nd
Slide 10: Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer (PROC)
10 Forward-Looking Statements Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer (PROC) 5th LEADING CAUSE OF DEATH among women in the U.S. ~70% OF PATIENTS are diagnosed with advanced disease 50% 5-YEAR relative survival (9-12 months PROC) LESS THAN Ovarian Cancer © 2021 Aravive, Inc.
Slide 11: AVB-500 PROC: Phase 1a and 1b PK/PD Summary Data
11 AVB-500 PROC: Phase 1a and 1b PK/PD Summary Data AVB-500 q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1 of 28-day cycle; Paclitaxel (PAC) 80 mg/m2 day 1, day 8, day 15 of 28-day cycle; Maintenance dosing on AVB-500 monotherapy PROC = platinum-resistant ovarian cancer iDMC= Independent
Slide 12: Time on Treatment for AVB-500 + Paclitaxel Patients
Time on Treatment for AVB-500 + Paclitaxel Patients (10 and 15mg/kg groups) 12 © 2021 Aravive, Inc.
Slide 13: Encouraging PFS Trends Above Minimal Efficacious Concentration
13 Encouraging PFS Trends Above Minimal Efficacious Concentration for AVB-500 + Paclitaxel Patients © 2021 Aravive, Inc. Exposure response (E-R) analysis demonstrated that subjects with cycle 1 trough concentrations (C1D15) >13.8mg/L (minimal efficacious concentration; MEC) had longer mPFS relative
Slide 14: AVB-500 / Paclitaxel Combination Clinical Activity
14 AVB-500 / Paclitaxel Combination Clinical Activity Note: AVB-500 + PAC and >MEC in bev naïve patients (n=7): mPFS 9.1 months and ORR of 71% Note: AVB-500 + PAC and <MEC: mPFS 2.8 months * Study ongoing so data can change; ** MEC = minimal efficacious concentration (13.8mg/L) For reference, subgro
Slide 15: sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo
15 sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo Serum levels of sAXL/GAS6 ratio (potential biomarker) correlated with response to AVB-500 + Chemo sAXL/GAS6 ratio above 0.773 (N=11) led to clinical benefit rate of 82% with CR/PR/SD rates of 18%, 36%, 27%, respectively CBR = clinical be
Slide 16: mPFS & mOS Longer in Patients Who Did Not Receive Bevacizumab
16 mPFS & mOS Longer in AVB-500 + PAC Patients Who Did Not Receive Bevacizumab and Whose Baseline sAXL/GAS6 >0.773 © 2021 Aravive, Inc.
Slide 17: Promising Responses in Patients > MEC with Poor Prognostic Indicators
17 Promising Responses in Patients > MEC with Poor Prognostic Indicators CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS WITH <3MO PLATINUM FREE INTERVAL** (N=21) CLINICAL RESPONSE OF CHEMOTHERAPY IN 3rd LINE AND 4th LINE*** (N=99) *All doses and both chemo cohorts; **Historical data from Cancer Chemo
Slide 18: Dose Selection for AVB-500 Phase 3 Trial in PROC
18 Dose Selection for AVB-500 Phase 3 Trial in PROC 5/5 patients at 15mg/kg demonstrated clinical benefit: Consistent with hypothesis that trough levels are associated with clinical activity, all 5 evaluable patients in 15 mg/kg cohort achieved MEC by their first CT scan, following four doses of AVB
Slide 19: Strong Safety Profile of AVB-500
19 Strong Safety Profile of AVB-500 Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE severity and frequency are consistent with expectations of the conco
Slide 20: Conclusions/Recommendations for Registrational Trial in PROC
20 Conclusions/Recommendations for Phase 3 Registrational Trial in PROC P1b PK model simulations predict that 84.2% of subjects treated with RP2D of 15mg/kg would have a cycle 1 trough above the 13.8mg/L (MEC; minimal efficacious concentration) threshold established by the E-R analysis; all patients
Slide 21: Competitive Advantages of AVB-500 in PROC
21 Competitive Advantages of AVB-500 in PROC Favorable Safety Profile to Date NO DLTs like chemotherapies and ADCs NO dose reductions or discontinuations to manage toxicities NO toxicities that have been seen with ADCs: neutropenia, ocular toxicities, peripheral neuropathy, and/or liver enzyme eleva
Slide 22: Potentially More Favorable Benefit/Risk Profile vs Competitors
22 Potentially More Favorable Benefit/Risk Profile vs Competitors For illustrative purposes only, Data not generated from comparative study. Variation in study design including patient eligibility, response criteria, and assessment can affect outcomes and limit comparisons across studies. **Sources:
Slide 23: AVB-500 Phase 3 Adaptive Registrational Trial Design in PROC
FDA feedback: study could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time 23 Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Compare Efficacy and Tolerability of AVB-500 + PAC versus PAC (NCT04729608) AVB-500 Phase 3 Adaptive Reg
Slide 24: Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma
24 Forward-Looking Statements Second Indication: AVB-500 in Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma (ccRCC) 15% 70k RESISTANCE To CHEMO OVER LESS THAN 5-YEAR relative survival for metastatic renal cancer NEW CASES expected in the U.S. in 2020 Is Common © 2021 Aravive, Inc.
Slide 25: Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC
25 Forward-Looking Statements Strong Biological Rationale for AVB-500/Cabozantinib in ccRCC GAS6/AXL in clear cell Renal Cell Carcinoma (ccRCC)1 AXL plays significant role in ccRCC invasion & metastasis AXL highly expressed in aggressive ccRCC tumors and associated with poor outcome GAS6/AXL signali
Slide 26: Single Agent Activity in Highly Metastatic Renal Model (SN12L1)
26 Forward-Looking Statements Single Agent Activity in Highly Metastatic Renal Model (SN12L1) 5mg/kg AXL decoy administered twice/wk 10 mg/kg administered QOD Rankin et al, PNAS, September 16, 2014, vol. 111, no. 37, 13373–13378 Note: S6-1 and AVB-S6 are related AXL decoy proteins; both in S6 family
Slide 27: Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX
27 Forward-Looking Statements Synergistic Effect with AVB-500 & TKI Combo in TKI-Resistant Renal PDX AVB-500/Pazopanib Combination Significantly Reduced Growth Rate in TKI-Resistant Renal Patient-Derived Xenograft Models Xiao et al, Cancer Res 2019;79:5758–68; *note AVB-S6 is AVB-500 © 2021 Aravive,
Slide 28: AVB-500/Cabozantinib Phase 1b / Phase 2 Trial Design in ccRCC
28 Forward-Looking Statements AVB-500/Cabozantinib Phase 1b / Phase 2 Trial Design in ccRCC Phase 1b Trial of AVB-500 in Combination with Cabozantinib Up to 18 patients; ability to increase/decrease dose based on tolerability, PK/PD Histologically confirmed metastatic ccRCC and patient has progresse
Slide 29: Two IST-Sponsored Trials Studying AVB-500 in Combination with PDL1
29 Forward-Looking Statements Two IST-Sponsored Trials Studying AVB-500 in Combination with PDL1 AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ClinicalTrials.gov Identifier: NCT04019288 Status: Recruiting Spo
Slide 30: Strategic Collaboration with Wuxi Biologics for High-Affinity Bispecifics
30 Forward-Looking Statements Strategic Collaboration with Wuxi Biologics for High-Affinity Bispecifics Objective is to identify/develop novel, high-affinity bispecific antibodies against CCN2, also known as connective tissue growth factor (CTGF), targeting cancer/fibrosis using WuXiBody™ platform C
Slide 31: 3D Medicines Collaboration to Develop/Commercialize AVB-500 in China
31 Forward-Looking Statements 3D Medicines Collaboration to Develop/Commercialize AVB-500 in China Exclusive collaboration and license agreement for development & commercialization of AVB-500 across all oncology indications in mainland China, Hong Kong, Macau, and Taiwan (Greater China) Aravive rece
Slide 32: Development Strategy: Basket Trials to Efficiently Expand Pipeline
32 Forward-Looking Statements Development Strategy: Basket Trials to Efficiently Expand Pipeline Basket trials are common approach in oncology development (i.e., Keynote 021, Checkmate 12, Innova205, TOPACIO, EV-103, Mirvetuximab P1/2 combo, sitravatinib + PD-1 P1/2 combos) Cost effective approach t
Slide 33: AVB-500: Large Market Opportunities in PROC, ccRCC & Other Indications
33 AVB-500: Large Market Opportunities in PROC, ccRCC & Other Indications 2L-4L platinum-resistant ovarian cancer (PROC), high grade serous patients 2L advanced/metastatic clear cell renal cell carcinoma (ccRCC) patients HER2 negative 2L+ patients (includes HR positive and TNBC) Exocrine (adenocarci
Slide 34: Financial Summary
34 Forward-Looking Statements Financial Summary Shares outstanding – 19.0M* Net cash used in operating activities was $16.4 million for first nine months of 2020 Cash and cash equivalents as of 9/30/20 -approximately $54 million (Does not include (i) $12 million received from China licensing collabo
Slide 35: Upcoming Milestones
35 Forward-Looking Statements Upcoming Milestones Q1’2021 – Anticipate first-patient treated in Phase 3 PROC trial Q1’2021 – Anticipate first-patient treated in Phase 1 ccRCC trial Q3’2021 – Anticipate completion of enrollment in Phase 1b ccRCC trial Q4’2021 – Anticipate initiation of Phase 2 ccRCC
Slide 36: Thank you!
Thank you! Halting Disease Progression in its Tracks